Same Drug Class

Ipilimumab vs Nivolumab

Ipilimumab vs Nivolumab: Overview

This comparison examines the pharmacological differences between Ipilimumab and Nivolumab.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Ipilimumab β€” 14.7 days; Nivolumab β€” 27 days.

Chemical Properties

Type: Ipilimumab β€” Antibody; Nivolumab β€” Antibody.